Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints. On Monday, the pharmaceutical company said it has received positive topline results ...

Five patients (4-9 yrs.) presented in five years with primary pulmonary hypertension (PPH). Each was initially evaluated for seizures or syncope. Two sisters (#1s2) were Hispanic and resided at ...

The AJMC® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure ...

Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial and actively enrolling ...

Ann Intern Med. 2005;143:282-292. 5. Nathan SD, Shlobin OA, Ahmad S, et al. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest. 2007;131:657-663. 6.

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334 (5):296-301. doi: 10.1056/NEJM199602013340504 ...

Cite this: Patrice Wendling. Pulmonary Artery Denervation Takes Next Step in Hypertension - Medscape - Sep 18, 2022. Authors and Disclosures Authors and Disclosures Author (s) ...

- Conference call and webcast with guest pulmonary key opinion leaders to be held today, Monday, January 27th at 5:00 p.m. EST - January 27, 2020 04:01 PM Eastern Standard Time ...